BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Alexion Pharmaceuticals\, Inc. (subsidiary of AstraZeneca) rea
 douts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Alexion Pharmaceuticals\, Inc. (s
 ubsidiary of AstraZeneca)'s drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06724809-886@assetmemo.bio
DTSTAMP:20261121T010452Z
DTSTART;VALUE=DATE:20261207
DTEND;VALUE=DATE:20261208
SUMMARY:Soliris (Eculizumab): Phase 3 readout est. (NCT06724809)
DESCRIPTION:Soliris (Eculizumab)\, phase 3.\nStudy: Efficacy\, Safety\, PK\
 , PD\, and ADA of Eculizumab in Chinese Adults With NMOSD\nEstimated prima
 ry completion: 7 December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/eculizumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06724809
URL:https://assetmemo.bio/drug/eculizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06449001-886@assetmemo.bio
DTSTAMP:20261121T010452Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:Soliris (Eculizumab): Phase 3 readout est. (NCT06449001)
DESCRIPTION:Soliris (Eculizumab)\, phase 3\, Paroxysmal Nocturnal Hemoglobi
 nuria.\nStudy: Study of Danicopan as Add-on Treatment to Ravulizumab or Ec
 ulizumab in Pediatric Participants With PNH Who Have Clinically Significan
 t Extravascular Hemolysis\nEstimated primary completion: 28 May 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/eculizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06449001
URL:https://assetmemo.bio/drug/eculizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07160608-10336@assetmemo.bio
DTSTAMP:20261121T010452Z
DTSTART;VALUE=DATE:20271011
DTEND;VALUE=DATE:20271012
SUMMARY:ALXN1820: Phase 2 readout est. (NCT07160608)
DESCRIPTION:ALXN1820\, phase 2\, ANCA-Associated Vasculitis.\nStudy: Safety
  and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil C
 ytoplasmic Antibody (ANCA)-Associated Vasculitis\nEstimated primary comple
 tion: 11 October 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/alxn1820#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07160608
URL:https://assetmemo.bio/drug/alxn1820#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04988386-11047@assetmemo.bio
DTSTAMP:20261121T010452Z
DTSTART;VALUE=DATE:20280415
DTEND;VALUE=DATE:20280416
SUMMARY:Attruby (Acoramidis): Phase 3 readout est. (NCT04988386)
DESCRIPTION:Attruby (Acoramidis)\, phase 3.\nStudy: Open-Label Safety Study
  of Acoramidis (AG10) in Symptomatic ATTR Participants\nEstimated primary 
 completion: 15 April 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/acoramidis#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04988386
URL:https://assetmemo.bio/drug/acoramidis#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563895-11047@assetmemo.bio
DTSTAMP:20261121T010452Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Attruby (Acoramidis): Phase 3 readout est. (NCT06563895)
DESCRIPTION:Attruby (Acoramidis)\, phase 3.\nStudy: Acoramidis Transthyreti
 n Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptoma
 tic Carriers of a Pathogenic TTR Variant\nEstimated primary completion: Oc
 tober 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/acoramidi
 s#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 563895
URL:https://assetmemo.bio/drug/acoramidis#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07116473-11047@assetmemo.bio
DTSTAMP:20261121T010452Z
DTSTART;VALUE=DATE:20371130
DTEND;VALUE=DATE:20371201
SUMMARY:Attruby (Acoramidis): Phase 3 readout est. (NCT07116473)
DESCRIPTION:Attruby (Acoramidis)\, phase 3\, Transthyretin Amyloidosis with
  Cardiomyopathy.\nStudy: To Evaluate the Long-term Safety and Tolerability
  of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE
 )\nEstimated primary completion: November 2037. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/acoramidis#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07116473
URL:https://assetmemo.bio/drug/acoramidis#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
